A Phase 3 Multicenter, Randomized, Open-label, Clinical Trial of Telavancin Versus Standard Intravenous Therapy in the Treatment of Subjects With Staphylococcus Aureus Bacteremia Including SA Right-sided Infective Endocarditis

Trial Profile

A Phase 3 Multicenter, Randomized, Open-label, Clinical Trial of Telavancin Versus Standard Intravenous Therapy in the Treatment of Subjects With Staphylococcus Aureus Bacteremia Including SA Right-sided Infective Endocarditis

Recruiting
Phase of Trial: Phase III

Latest Information Update: 31 Aug 2017

At a glance

  • Drugs Telavancin (Primary) ; Cefazolin; Daptomycin; Penicillins; Vancomycin
  • Indications Bacteraemia; Bacterial endocarditis; Staphylococcal infections
  • Focus Registrational; Therapeutic Use
  • Sponsors Theravance Biopharma
  • Most Recent Events

    • 08 Mar 2017 Planned End Date changed from 1 Oct 2017 to 1 May 2018.
    • 08 Mar 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Mar 2018.
    • 08 Aug 2016 According to a Theravance Biopharma media release, the company plans to complete this study in 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top